Next Article in Journal
Non-Invasive Prenatal Screening: The First Report of Pentasomy X Detected by Plasma Cell-Free DNA and Karyotype Analysis
Next Article in Special Issue
The Mesenchymal Niche in Myelodysplastic Syndromes
Previous Article in Journal
Anti-CK7/CK20 Immunohistochemistry Did Not Associate with the Metastatic Site in TTF-1-Negative Lung Cancer
Previous Article in Special Issue
Myelodysplastic Syndrome: Diagnosis and Screening
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

VEXAS Syndrome: A Novelty in MDS Landscape

1
Cochin Hospital, Université de Paris, F-75006 Paris, France
2
Institut Cochin, Université de Paris Cité, CNRS UMR8104, INSERM U1016, F-75014 Paris, France
*
Author to whom correspondence should be addressed.
Diagnostics 2022, 12(7), 1590; https://doi.org/10.3390/diagnostics12071590
Submission received: 10 June 2022 / Revised: 27 June 2022 / Accepted: 28 June 2022 / Published: 29 June 2022
(This article belongs to the Special Issue Myelodysplastic Syndrome: Diagnosis and Screening)

Abstract

Fever, inflammation and vacuoles in hematopoietic cells represent the main features associated with VEXAS syndrome, a new prototype of autoinflammatory disorders genetically characterized by somatic mutation of the UBA1 gene which encodes the enzyme1-activating enzyme (E1) required for ubiquitin signaling. Described very recently, patients with VEXAS syndrome present a systemic autoinflammatory syndrome associated with hematological impairments, especially cytopenias whose pathophysiology is mainly non-elucidated. Initially diagnosed in elderly male patients, VEXAS syndrome was frequently associated with a diagnosis of myelodysplastic syndromes (MDS) leading the medical community to first consider VEXAS syndrome as a new subtype of MDS. However, since the first description of VEXAS patients in 2021, it appears from the multitude of case reports that MDS associated with VEXAS are different from the classically described MDS.
Keywords: autoinflammatory disease; VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome; myelodysplastic syndrome autoinflammatory disease; VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome; myelodysplastic syndrome

Share and Cite

MDPI and ACS Style

Templé, M.; Kosmider, O. VEXAS Syndrome: A Novelty in MDS Landscape. Diagnostics 2022, 12, 1590. https://doi.org/10.3390/diagnostics12071590

AMA Style

Templé M, Kosmider O. VEXAS Syndrome: A Novelty in MDS Landscape. Diagnostics. 2022; 12(7):1590. https://doi.org/10.3390/diagnostics12071590

Chicago/Turabian Style

Templé, Marie, and Olivier Kosmider. 2022. "VEXAS Syndrome: A Novelty in MDS Landscape" Diagnostics 12, no. 7: 1590. https://doi.org/10.3390/diagnostics12071590

APA Style

Templé, M., & Kosmider, O. (2022). VEXAS Syndrome: A Novelty in MDS Landscape. Diagnostics, 12(7), 1590. https://doi.org/10.3390/diagnostics12071590

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop